loading...

Skindex (Skindex, Skindex-29, Skindex-16)

Chren MM

Distributed by Mapi Research Trust

ProQolid

Distributed by Mapi Research Trust

Basic description

Developed in 1996, 1997 and 2001 respectively.

The original 62-item-version of Skindex cannot be used.

An adolescent version also exists: Skindex-Teen.

Skindex-29 is a revised 29-items version of Skindex. Skindex-16 is a single-page version of Skindex.

Authors

Chren MM

Copyright
Skindex© MM Chren, 1996; Skindex16 © The Regents of the University of California, 2001; Skindex29 © MM Chren, 1997
Objective
To measure the effects of skin disease on patients' quality of life
Therapeutic area
  • Skin and Connective Tissue Diseases
Therapeutic indication

Generic for Skin and Connective Tissue Diseases

Type of Clinical Outcome Assessment (COA)
  • pro PRO
Original language(s)
  • English for the USA
Bibliographic reference(s) of the original questionnaire

Chren MM, Lasek RJ, Quinn LM, Mostow EN, Zyzanski SJ. Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness. J Invest Dermatol. 1996 Nov;107(5):707-13 (PubMed abstract)

Chren MM, Lasek RJ, Quinn LM, Covinsky KE. Convergent and discriminant validity of a generic and a disease-specific instrument to measure quality of life in patients with skin disease. J Invest Dermatol. 1997 Jan;108(1):103-7 (PubMed abstract)

Chren MM, Lasek RJ, Flock SA, Zyzanski SJ. Improved discriminative and evaluative capability of a refined version of skindex, a quality-of-life instrument for patients with skin diseases. Arch Dermatol. 1997 Nov;133:1433,1440 (PubMed abstract)

Chren MM, Lasek RJ, Sahay AP, Sands LP. Measurement of properties of skindex-16, a brief quality-of-life measure for patients with skin diseases. J Cutan Med Surg. 2001 Mar-Apr;5(2):105-10 (PubMed abstract)

Access this questionnaire

Please proceed below

Login SIGN up free

Contact and conditions of use

Authors

Chren MM

Professor
University of California at San Francisco
2340 Sutter Street, N412
Mail Code:  Box 0808
San Francisco, CA 94143-0808
USA
Fax: +1 (415) 476-6751
Mary-Margaret Chren publications (PubMed)

Contact information

Mapi Research Trust
PROVIDE™
27 rue de la Villette
69003 Lyon
France
Phone: +33 (0)4 72 13 66 66

Conditions of use

Students, physicians, clinical practice, not-funded academic users

You may access available translations of the questionnaire directly (see tutorial). Should you not see the Download button, please contact us.

Funded academic users, healthcare organizations, commercial users & IT companies

Fees may apply to your project. Submit your request (see tutorial). Our PROVIDE team will get back to you with the needed information and license agreement in a timely manner.

Review copy

Examination copies can only be used for the limited purpose of examining the suitability of the Questionnaire for subsequent research and/or clinical use, and cannot be used in research or in clinical practice or distributed to others.
You are not authorized to modify, retype, translate, copy or otherwise duplicate the Questionnaire except with the further and prior written permission of Mapi Research Trust / the developers / copyright holders / distributors.

Languages

Original language(s)

  • English for the USA

Translations

The list of available translations is subject to constant changes and may not be exhaustive. It is provided for information only. Some recently produced translations may not be included in the list below yet. Please do check the status of available translations with Mapi Research Trust / the developers / copyright holders / distributors.

Also, the listed translations may not have undergone a full linguistic validation process and may require further work to be suitable for use in a study.

Skindex

French for France

Skindex 16 AU2.1

Arabic for Israel*
Danish for Denmark*
English for New Zealand*
Estonian for Estonia*
French for Belgium*
French for France*
German for Germany*
Hebrew for Israel*
Hindi for India
Hungarian for Hungary*
Italian for Italy*
Italian for Switzerland*
Latvian for Latvia*
Lithuanian for Lithuania*
Norwegian for Norway*
Portuguese for Brazil*
Portuguese for Portugal*
Russian for Estonia*
Russian for Israel*
Russian for Latvia*
Spanish for Colombia*
Spanish for Peru*
Spanish for Puerto Rico*
Spanish for the USA*
Swedish for Sweden*
Ukrainian for Ukraine*

Skindex-16 AU2.0

Arabic for Saudi Arabia
Arabic for Tunisia
Bulgarian for Bulgaria*
Czech for Czech Republic*
Dutch for Belgium (Flemish)*
Dutch for the Netherlands*
English for Australia*
English for Canada*
English for the UK*
French for Canada*
Hindi for India
Japanese for Japan*
Korean for Korea
Malay for Malaysia
Mandarin for the USA*
Polish for Poland*
Portuguese for Brazil*
Romanian for Romania*
Russian for Russia*
Spanish for Argentina*
Spanish for Mexico*
Spanish for Spain*
Ukrainian for Ukraine

Skindex-29

Arabic for Israel*
Bulgarian for Bulgaria*
Czech for Czech Republic
Danish for Denmark*
Dutch for Belgium (Flemish)*
Dutch for the Netherlands*
English for Australia
English for Canada*
English for the UK*
French for Belgium*
French for Canada*
French for France*
German for Austria
German for Germany*
German for Switzerland
Greek for Greece*
Hebrew for Israel*
Hungarian for Hungary
Italian for Italy*
Japanese for Japan*
Korean for Korea
Mandarin for Taiwan*
Polish for Poland*
Portuguese for Brazil
Portuguese for Portugal
Russian for Israel*
Russian for Ukraine*
Spanish for Argentina*
Spanish for Mexico
Spanish for Spain*
Spanish for the USA*
Turkish for Turkey*
Ukrainian for Ukraine*
* Performed by Mapi

BiblioPRO: you can find information about the Spanish version here - puede encontrar información sobre la versión española aqui

The author has selected Mapi/ICON Language Services as exclusive linguistic validation company to ensure the production of harmonized and consistent language versions.

For additional information on available translations of this instrument, or for a project involving new languages, please submit a request (tutorials available on our FAQs).

Conditions to translate

Academic Translation

If you wish to translate the questionnaire:

  1. Log in or Register for free
  2. Submit your request for translation online (Tutorials are available on our FAQs)
  3. Our PROVIDE team will send you a translation agreement along with Linguistic Validation Guidelines.

Commercial Users

Exclusive vendor for translation work for commercial users: Mapi/ICON Language Services

More information on translations

Skindex:

Bibliographic reference of the French translation:

Leplege A, Ecosse E, Zeller J, Revuz J, Wolkenstein P. [The French version of Skindex (Skindex-France). Adaptation and assessment ofpsychometric properties] Ann Dermatol Venereol. 2003 Feb;130(2 Pt 1):177-83.

Skindex-29: 

Bibliographic reference of the Brazilian Portuguese translation:

de Paula HR, Dini GM, Haddad A, Ferreira LM, Weiss MA. Translation, cultural adaptation, and validation of the American Skindex-29 quality of life index. Anais Brasileiros de Dermatologia. 2014;89(4):599-607. (for Brazilian Portuguese)

Paula HR, Haddad A, Weiss MA, Dini GM, Ferreira LM. Translation, cultural adaptation, and validation of the American Skindex-29 quality of life index. Anais Brasileiros de Dermatologia. 2014;89(4):600-7.

Bibliographic reference of the Chinese translation:

He Z, Lu C, Chren MM, Zhang Z, Li Y, Ni X, et al. Development and psychometric validation of the Chinese version of Skindex-29 and Skindex-16. Health and quality of life outcomes. 2014;12:190.

Bibliographic reference of the Colombian translation:

Vasquez D, Aguirre DC, Sanclemente G. Construct and convergent/ discriminant validity and responsiveness of the Colombian version of Skindex-29. Dermatologie in Beruf und Umwelt. 2018;66 (1):39-40.

Vasquez D, Aguirre D, Sanclemente G. Construct validity and responsiveness of the Colombian version of Skindex-29. The British journal of dermatology. 2019;06.

Bibliographic reference of the German translation:

Augustin M, Wenninger K, Amon U, Schroth MJ, Kuster W, Chren M, Kupfer J, Gieler U. German adaptation of the Skindex-29 questionnaire on quality of life in dermatology: validation and clinical results. Dermatology. 2004;209(1):14-20

Bibliographic reference of the Italian translation:

Abeni D, Picardi A, Pasquini P, Melchi CF, Chren MM. Further evidence of the validity and reliability of the Skindex-29: an Italian study on 2,242 dermatological outpatients. Dermatology. 2002;204(1):43-9

Bibliographic reference of the Polish translation:

Janowski K, Steuden S, Bereza B. The polish version of Skindex-29: Psychometric properties of an instrument to measure quality of life in dermatology. Postepy Dermatologii i Alergologii. 2014;31(1):12-20.

Bibliographic reference of the Portuguese translation:

Carvalho D, Aguiar P, Palma-Carlos A. Validation of the skindex-29 questionnaire: Portuguese version (Portugal). Acta Medica Portuguesa. 2018;31(9):463-9.

Bibliographic reference of the Serbian translation:

Milutinovic JD, Krstic N, Jankovic SM. Translation and validation of the Serbian version of the Skindex-29 instrument for measuring impact of skin disease on quality of life. Acta Dermatovenerologica Croatica. 2017;25(2):120-4.

Bibliographic references of the Spanish translation:

Jones-Caballero M, Penas PF, Garcia-Diez A, Chren MM, Badia X. [The Spanish version of Skindex-29. An instrument for measuring quality of life in patients with cutaneous diseases] Med Clin (Barc). 2002 Jan 19;118(1):5-9.

Jones-Caballero M, Penas PF, Garcia-Diez A, Badia X, Chren MM. The Spanish version of Skindex-29. Int J Dermatol. 2000 Dec;39(12):907-12

Bibliographic reference of the Tukish translation:

Aksu AEK, Urer MS, Sabuncu I, Saracoglu ZN, Chren MM. Turkish version of Skindex-29. International Journal of Dermatology. 2007;46(4):350-5.

Skindex-16:

Bibliographic reference of the Arabic translation:

Alghamdi KM, Alshammari SA. Arabic version of Skindex-16: Translation and cultural adaptation, with assessment of reliability and validity. Int J Dermatol. 2007 Mar;46(3):247-52

Member Access

Subscribe to PROQOLID to access to full information

Access to advanced descriptions of Clinical Outcome Assessments (COAs)

A question? Contact us